CHRISTOPHER BOJRAB: Open Payments
NPI 1689659013 · CARMEL, IN. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$104,564 in 289 payments from 21 companies in 2025. Trend: 2023 $199,999 · 2024 $136,139 · 2025 $104,564
Speaker / faculty: $51,997Honoraria: $25,114Consulting: $13,916Food & beverage: $6,868Travel & lodging: $5,539Speaker / faculty: $1,050
| Company | Payments | Amount |
|---|---|---|
| Axsome Therapeutics, Inc. | 53 | $27,176 |
| ABBVIE INC. | 59 | $26,022 |
| Vanda Pharmaceuticals Inc. | 52 | $18,218 |
| Eli Lilly and Company | 6 | $12,058 |
| Teva Pharmaceuticals USA, Inc. | 16 | $8,968 |
| Otsuka America Pharmaceutical, Inc. | 22 | $5,790 |
| E.R. Squibb & Sons, L.L.C. | 15 | $3,446 |
| Noven Therapeutics, LLC | 2 | $1,050 |
| Neurocrine BioSciences, Inc. | 21 | $451 |
| JAZZ PHARMACEUTICALS INC. | 7 | $413 |
Products named: Auvelity, VRAYLAR, FANAPT, AUSTEDO XR, REXULTI, COBENFY, Xelstrym, HETLIOZ.
Industry payments across IN — which companies pay providers there.
